PORT WASHINGTON, NY – November 14, 2017 – Pall Corporation, a global leader in filtration, separation and purification, is pleased to debut new Cadence Inline Diafiltration (ILDF) modules for scalable single-pass diafiltration (DF) to provide repeated downstream dilution and concentration cycles without a recirculation loop. The modules enable fully continuous DF processes in ultrafiltration and DF (UF/DF) processing steps, and are available in a range of size formats to accommodate various processing volumes, as well as being able to be used in one or more locations of a continuous mAb downstream purification process. The modules will be exclusively showcased this week during the next installation of Pall’s Leadership Forum series hosted in the Westborough, MA Center of Excellence.


“Single-pass tangential flow filtration, or SPTFF, revolutionized how TFF is implemented in biotech, vaccine, blood plasma and other applications, yet challenges remained,” commented Mario Philips, Vice President & General Manager of Pall Life Sciences. “The Cadence ILDF device eliminates those challenges, making continuous processing of the final UF/DF of drug substance possible, and takes another step forward in Pall delivering the only viable end-to-end integrated continuous bioprocessing platform on the market. We are excited to preview the technology to key customers and business colleagues this week in Westborough.”


Standard Pall T-Series cassettes act as the building blocks for the new Cadence ILDF module, which is offered with either Delta regenerated cellulose or OmegaTM polyethersulfone membranes to provide high flux, high selectivity and low protein binding characteristics. Users will experience removal factors of ≥ 3-log, in a scalable, accurate platform that has proven selectivity and low protein binding attributes. The modules enable significantly reduced system hold-up volume, and feature an easy to use, holderless design. Each module is supplied with comprehensive documentation and validation materials, as well as access to Pall’s world-class training and technical support teams to develop and optimize processes.


To learn more about the new Cadence ILDF offer, please visit www.pall.com/biopharm. Or, to start a conversation with a Pall representative, including getting further details about attending future Pall Leadership Forums, please email biopharm@pall.com. Keep up with the Pall Life Sciences division on social media: LinkedInTwitterYouTube


About Pall Corporation

Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.

For more information visit www.pall.com.

Or follow us on social media: Google+ - YouTube -   LinkedIn - Twitter - Facebook



Corporate Media Contact

Pall Corporation

Mariann Kourafas

Director of Communications



Media Contact

White Matter Communications

Beth Willers



More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing
September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development